Saturday 17 October 2026
Export NRIX’s income statement to Excel — free account
Nurix Therapeutics, Inc.
NRIX Healthcare Biotechnology
Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024. In the quarter to August 2026, revenue grew 8,426.3%, EPS grew 578.5% and free cash flow grew 1,122.1%, each against the same quarter a year earlier.
24.42
0.53
−2.12%
Follow NRIX
| Nov '25 | Nov '24 | Nov '23 | Nov '22 | Nov '21 | Nov '20 | Nov '19 | Nov '18 | Nov '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
4 | 3 | 4 | 3 | 2 | 4 | — | — | — |
Altman Z-Score |
3.77 | 4.68 | (1.36) | 1.20 | 4.73 | 3.68 | — | — | — |
P/S ratio |
17.45 | 26.44 | 4.39 | 15.59 | 41.55 | 37.49 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
1.20 | 3.28 | (2.72) | 0.62 | 2.87 | 5.12 | (5.00) | (3.56) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.52 | 1.52 | — |
P/Operating CF |
(21.61) | (29.59) | 12.66 | (15.87) | (39.99) | (32.61) | (4.92) | (4.92) | — |
Beneish M-Score |
— | — | — | — | (2.21) | — | — | — | — |
P/B ratio |
2.72 | 2.74 | 1.69 | 1.98 | 3.61 | 2.30 | 0.00 | 0.00 | — |
Price to Tangible BV |
2.72 | 2.74 | 1.69 | 1.98 | 3.61 | 2.30 | 0.00 | 0.00 | — |
EV/Sales |
10.39 | 15.27 | 0.65 | 7.59 | 31.61 | 21.71 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(3.50) | (4.83) | (0.62) | (1.83) | (11.15) | (4,835.44) | (2.04) | (2.04) | — |
EV/FCF |
(3.31) | (4.58) | (0.56) | (1.70) | (10.45) | (83.50) | (2.19) | (2.19) | — |
Quick Ratio |
6.86 | 6.36 | 3.31 | 4.38 | 4.56 | 6.40 | 2.34 | 1.19 | — |
Current Ratio |
7.02 | 6.46 | 3.40 | 4.51 | 4.70 | 6.70 | 2.44 | 1.24 | — |
Net Debt/EBITDA |
2.14 | 2.93 | 1.96 | 1.79 | 2.69 | 4.50 | 1.89 | 5.49 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.12 | 0.11 | 0.20 | 0.09 | 0.07 | 0.08 | 0.70 | 1.65 | — |
Operating CF/Net income |
0.94 | 0.89 | 0.57 | 0.89 | 0.72 | 0.00 | (0.03) | 3.36 | — |
Capex/Depreciation |
(1.64) | (1.80) | (1.02) | (1.09) | (0.73) | (1.86) | (0.74) | (0.60) | — |
| (49.63%) | (53.22%) | (57.10%) | (55.84%) | (37.05%) | (37.19%) | 45.89% | 19.94% | — | |
| (38.96%) | (37.77%) | (37.27%) | (40.37%) | (26.85%) | (19.64%) | (48.52%) | (41.54%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (158.17%) | (445.28%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(48.72%) | (35.76%) | (63.88%) | (68.07%) | (45.74%) | (16.60%) | (80.11%) | (77.00%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 76.12 | 78.78 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
377.36% | 406.30% | 245.69% | 477.64% | 391.37% | 373.14% | 144.71% | 108.18% | — |
Selling, General and Administrative Expense of Revenue |
62.80% | 84.23% | 55.73% | 98.37% | 104.88% | 91.52% | 26.76% | 17.82% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
45.21% | 62.20% | 43.74% | 72.83% | 53.11% | 24.14% | 1.64% | 1.15% | — |
Graham Net Nets |
0.31 | 0.33 | 0.42 | 0.34 | 0.14 | 0.29 | (1.10) | (1.10) | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(17.98%) | (13.45%) | (42.60%) | (30.10%) | (9.47%) | (7.21%) | (4.00%) | (4.00%) | — |
Free Cash Flow Yield |
(17.98%) | (12.61%) | (26.56%) | (28.57%) | (7.28%) | (0.69%) | 65.89% | 65.89% | — |
Revenue per Share |
0.97 | 0.81 | 1.42 | 0.79 | 0.69 | 1.14 | 9.45 | 13.29 | — |
Operating CF per Share |
(2.88) | (2.57) | (1.50) | (3.29) | (1.97) | (0.01) | 0.18 | (11.24) | — |
Capex per Share |
(0.16) | (0.14) | (0.15) | (0.25) | (0.13) | (0.29) | (0.50) | (0.56) | — |
Free Cash Flow per Share |
(3.04) | (2.71) | (1.65) | (3.54) | (2.10) | (0.30) | (0.32) | (11.81) | — |
Cash per Share |
6.84 | 9.08 | 5.30 | 6.36 | 6.89 | 17.94 | 11.45 | 13.86 | — |
Shareholders Equity per Share |
6.22 | 7.85 | 3.69 | 6.25 | 7.98 | 18.52 | (17.53) | (13.08) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
6.22 | 7.85 | 3.69 | 6.25 | 7.98 | 18.52 | (17.53) | (13.08) | — |
Free Cash Flow |
(263.47) | (181.86) | (89.77) | (172.05) | (90.03) | (4.63) | (1.05) | (33.26) | — |
Working Capital |
520.35 | 523.53 | 208.55 | 247.79 | 244.86 | 253.90 | 23.22 | 7.82 | — |
Capital Expenditures |
(14.00) | (9.27) | (8.40) | (12.24) | (5.66) | (4.55) | (1.65) | (1.59) | — |
Net Current Asset Value |
457.43 | 477.04 | 140.40 | 205.39 | 176.65 | 192.36 | (62.41) | (41.59) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.17 | 0.17 | 0.11 | 0.32 | 0.19 | 0.26 | 0.05 | 0.04 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.38 | 0.29 | 0.49 | 0.65 | 0.69 | 0.37 | 0.58 | 0.60 | — |
Cash ROIC |
(23.28%) | (16.00%) | (18.38%) | (28.07%) | (14.11%) | (0.81%) | 5.25% | (1,517.52%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 10.58 | 5.92 | 1.93 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
— | — | — | 3.65 | 5.03 | 9.23 | — | — | — |
Average Payables |
11.35 | 8.94 | 5.73 | 5.86 | 5.03 | 2.51 | 1.45 | 1.45 | — |
Average Assets |
678.74 | 512.47 | 386.18 | 446.77 | 436.56 | 220.20 | 44.72 | 22.70 | — |
Average Common Equity |
532.87 | 363.74 | 252.09 | 323.00 | 316.29 | 116.28 | (47.28) | (47.28) | — |
Columns are period end dates · fundamentals updated 15 Oct 2026